D

Devyser Diagnostics AB
STO:DVYSR

Watchlist Manager
Devyser Diagnostics AB
STO:DVYSR
Watchlist
Price: 129 SEK -1.9% Market Closed
Market Cap: 2.1B SEK
Have any thoughts about
Devyser Diagnostics AB?
Write Note

Devyser Diagnostics AB
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Devyser Diagnostics AB
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
D
Devyser Diagnostics AB
STO:DVYSR
Total Equity
kr385.1m
CAGR 3-Years
132%
CAGR 5-Years
67%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Total Equity
kr2B
CAGR 3-Years
5%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Total Equity
kr661.8m
CAGR 3-Years
32%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Total Equity
kr13.1B
CAGR 3-Years
32%
CAGR 5-Years
50%
CAGR 10-Years
42%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Total Equity
kr37.1B
CAGR 3-Years
19%
CAGR 5-Years
19%
CAGR 10-Years
23%
BioArctic AB
STO:BIOA B
Total Equity
kr1B
CAGR 3-Years
5%
CAGR 5-Years
1%
CAGR 10-Years
N/A
No Stocks Found

Devyser Diagnostics AB
Glance View

Market Cap
2.1B SEK
Industry
Biotechnology

Devyser Diagnostics AB engages in the development, manufacture and sale of kits for genetic testing in routine diagnostics. The company is headquartered in Hagersten, Stockholm. The company went IPO on 2021-12-10. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The firm has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The firm provides its products in more than 45 countries.

DVYSR Intrinsic Value
124.21 SEK
Overvaluation 4%
Intrinsic Value
Price
D

See Also

What is Devyser Diagnostics AB's Total Equity?
Total Equity
385.1m SEK

Based on the financial report for Dec 31, 2023, Devyser Diagnostics AB's Total Equity amounts to 385.1m SEK.

What is Devyser Diagnostics AB's Total Equity growth rate?
Total Equity CAGR 5Y
67%

Over the last year, the Total Equity growth was -11%. The average annual Total Equity growth rates for Devyser Diagnostics AB have been 132% over the past three years , 67% over the past five years .

Back to Top